Debating Frontline Therapy in Chronic Myeloid Leukemia.
作者信息
Bi Xia, Ramanathan Sabarina, Keiffer Gina
机构信息
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States.
出版信息
Front Oncol. 2021 Sep 8;11:708823. doi: 10.3389/fonc.2021.708823. eCollection 2021.
Abstract
摘要
相似文献
1
Debating Frontline Therapy in Chronic Myeloid Leukemia.慢性髓性白血病一线治疗的争论
Front Oncol. 2021 Sep 8;11:708823. doi: 10.3389/fonc.2021.708823. eCollection 2021.
2
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia.慢性髓性白血病患者的酪氨酸激酶抑制剂测序
Oncol Ther. 2019 Dec;7(2):95-100. doi: 10.1007/s40487-019-00098-w. Epub 2019 Aug 8.
3
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.LYN 和 PTEN 基因在慢性髓性白血病中的表达及其在治疗策略中的重要性。
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.
4
Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.慢性期慢性髓性白血病一线治疗后的转归
Leuk Lymphoma. 2015 Mar;56(3):568-76. doi: 10.3109/10428194.2014.918969. Epub 2014 Jul 23.
5
[Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].[慢性髓性白血病患者使用酪氨酸激酶抑制剂期间血管不良事件的管理]
Rinsho Ketsueki. 2020;61(9):1018-1027. doi: 10.11406/rinketsu.61.1018.
6
Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.博舒替尼：一种用于慢性粒细胞白血病的第二代酪氨酸激酶抑制剂。
Ann Pharmacother. 2013 Dec;47(12):1703-11. doi: 10.1177/1060028013503124.
7
Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors.酪氨酸激酶抑制剂治疗在二线酪氨酸激酶抑制剂治疗失败后的慢性期慢性髓性白血病三线治疗中的疗效比较
Leuk Res. 2015 Jan;39(1):58-64. doi: 10.1016/j.leukres.2014.10.005. Epub 2014 Nov 1.
8
A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.对暴露于波纳替尼的伊马替尼敏感和伊马替尼耐药K562细胞中大分子变化的分子和生物物理比较
Tumour Biol. 2016 Feb;37(2):2365-78. doi: 10.1007/s13277-015-4015-9. Epub 2015 Sep 15.
9
Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis.慢性髓性白血病中的动脉高血压与酪氨酸激酶抑制剂：一项系统评价和荟萃分析
Front Pharmacol. 2021 Sep 22;12:674748. doi: 10.3389/fphar.2021.674748. eCollection 2021.
10
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.酪氨酸激酶抑制剂时代慢性髓性白血病急变期患者的预后因素及生存结果：477例患者的队列研究
Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25.
本文引用的文献
1
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.一线尼洛替尼对比伊马替尼治疗初诊慢性期慢性髓性白血病的长期疗效：ENESTnd 研究 10 年分析。
Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7.
2
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?应对慢性髓性白血病管理中的棘手问题：何时停用酪氨酸激酶抑制剂才安全？
Blood Adv. 2020 Nov 10;4(21):5589-5594. doi: 10.1182/bloodadvances.2020002538.
3
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.慢性髓性白血病临床实践指南（2021 年版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047.
4
Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.曲妥珠单抗仿制药的可及性和定价与慢性髓性白血病患者酪氨酸激酶抑制剂使用趋势的关系。
JAMA Oncol. 2020 Dec 1;6(12):1969-1971. doi: 10.1001/jamaoncol.2020.4660.
5
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.一线伊马替尼与第二代和第三代酪氨酸激酶抑制剂用于慢性期慢性粒细胞白血病的疗效比较：一项系统评价和荟萃分析。
Blood Adv. 2020 Jun 23;4(12):2723-2735. doi: 10.1182/bloodadvances.2019001329.
6
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
7
Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation.纳入停药策略的 CML 治疗方案的成本效益分析。
Blood Adv. 2019 Nov 12;3(21):3266-3277. doi: 10.1182/bloodadvances.2019000745.
8
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.使用第一代和第二代酪氨酸激酶抑制剂实现无治疗缓解。
Am J Hematol. 2019 Mar;94(3):346-357. doi: 10.1002/ajh.25342. Epub 2018 Nov 25.
9
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.慢性髓性白血病：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159.
10
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
Zotero 插件